Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma
Medical Oncology, 05/04/2012
Clinical Article
Kawashima A et al. – Continuing therapy for more than one course and maintaining more than 60 % of 1–month relative dose intensity were very important in the prolongation of progression–free survival time regardless of the initial treatment doses.



